STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Mela Sciences — Needham Growth Conference 2013
35 slides from STRATA Skin Sciences's conference presentation, Jan 17, 2013
Slide 1: MelaFind - Needham Growth Conference
MelaFind® Optics by Carl Zeiss Needham Growth Conference MELA Sciences, Inc. January 16, 2013 ©MELA Sciences 2012
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “e
Slide 3: Development History
Development History 1995 First application of computer vision technology to melanoma 1998 Initiation of development of MelaFind 2004 Protocol Agreement with FDA 2005 Initial Public Offering 2006 Establish commercial-grade manufacturing methods & supplier 2007-08 Execute pivotal trial 2009 PMA (Pre-M
Slide 4: Launch Progress Since March 2012
Launch Progress Since March 2012 13 Cities in Germany 25 States in US ©MELA Sciences 2012 MelaFind® Optics by Carl Zeiss
Slide 5: Commercial Strategy 1st months
Commercial Strategy 1st 12 months • Placement of MelaFind system ~$10,000 • ~$50/exam • Self-pay initially • Dermatologists • US – goal of 200 signed contracts • Germany – goal of 75 signed contracts ©MELA Sciences 2012 MelaFind® Optics by Carl Zeiss
Slide 6: Revenue Contributions YTD
Revenue Contributions 9 Mo’s YTD Sales COGS Gross Profit R & D G & A Other Total ELEMENTS OF REVENUE Initial Placement Fee: $2K of $10,000 ( $8K to “deferred revenue”) Placement Fee balance recognized @ $333/month for 24 months Card Sales - $2,500 per box of 50 (1 per patient) ($ Germany – alternate
Slide 7: 43.7M Medical & Cosmetic Procedures in the US per Year
43.7 M Medical & Cosmetic Procedures in the US per Year 37 Million Patients for Medical Visits1 13% 25% 20% 7% 2% 3% 3% 6% 3% 4% 11% Acne Skin Rash Skin Lesions, Moles & Other Skin Growths Warts Discoloration or Pigmentation Other Skin Symptoms Hair and scalp issues Skin Irritations Cancer, Skin & S
Slide 8: MelaFind increases dermatologist compensation
MelaFind increases dermatologist compensation, without taking time away from the patient MelaFind can add >$96,000/per year to a dermatologist’s compensation if used once an hour and charging $100 per session Average Income: Dermatologist by Geographical Area Source: Medscape Dermatology Compensatio
Slide 9: 2012 Accomplishments
2012 Accomplishments Launched MelaFind (March) Product upgrades Developed infrastructure for national business Many examples of clinical benefit of MelaFind Melanomas detected Unnecessary biopsies averted Ended year with over 100 signed user agreements Cleveland Clinic Top 10 Innovations for 2013; o
Slide 10: 2013 Goals
2013 Goals Drive toward goal of 275 signed use agreements by March 31, 2013 Expedite MelaFind practice integration & increased usage: 1. Practice commitment at time of placement 2. Peer to peer medical communications 3. Patient communications 4. Enhanced client services Reduce manufacturing costs si
Slide 11: 2013 Key Tactics
2013 Key Tactics Dermatology meetings 1. Winter Clinical 2. Orlando Derm Aesthetic & Clinical 1Q 2013 3. Winter Skin 4. Annual AAD meeting Agency (Rpr) efforts 1. Consumer Media & Skin Cancer Detection campaigns 2. Health & Beauty Magazine PR 3. Melanoma Monday campaign 4. Targeted patient mobilizat
Slide 12: Rpr Client & Industry Experience
Rpr Client & Industry Experience MELA Sciences 2012 MelaFind Optics by Carl Zeiss
Slide 13: Usage
Usage Rolling-out tactics to increase awareness of melanoma and MelaFind… increasing usage Do you have any moles on your body that look like these? Melanoma is the deadliest form of skin cancer, responsible for 75% of all skin cancer fatalities.1 But when treated early, melanoma is often curable.2 M
Slide 14: MelaFind Advertisements by dermatologists
MelaFind Advertisements by dermatologists MELA Sciences 2012 MelaFind Optics by Carl Zeiss
Slide 15: MelaFind Advertisements by MELA
MelaFind Advertisements by MELA IF YOU HAVE SKIN, YOU’RE AT RISK FOR MELANOMA.
Slide 16: MelaFind Chosen as Top Medical Innovation by Cleveland Clinic
MelaFind Chosen as One of Top 10 Medical Innovations for 2013 by Cleveland Clinic Criteria for Inclusion are Significant Clinical Impact, High Probability of Commercial Success, and Significant Human Interest Press Release: MELA Sciences, Inc. – Mon, Nov 5, 2012 7:00 AM EST NEW YORK, Nov. 5, 2012 (G
Slide 17: MelaFind Presence - 2013 Conference Schedule US
MelaFind ® Presence 2013 Conference Schedule – US Orlando Dermatology Aesthetic & Clinical Conf. – Jan. (Orlando, FL) Winter Clinical Dermatology Meeting – Jan. (Koloa, HI) Winter Skin Seminar – Jan. (UT) Annual American Academy of Dermatology Meeting – Mar. (Miami, FL) Atlantic Dermatological Confe
Slide 18: MelaFind Presence - Germany Conferences
MelaFind® Presence Upcoming Dermatology Conferences – Germany Dermatologische Praxis – Mar. (Frankenthal, Germany) 47th DDG-Session – May (Tagung, Germany) European PostASCO Meeting – TBD (Germany) Practical Dermatology & Venerology Conference (FOBI) – TBD (Germany) 8th World Congress of Melanoma –
Slide 19: Why Melanoma?
Why Melanoma? Melanoma kills 1 US citizen per hour 80% of all skin cancer deaths 50% increase in mortality since 1973 Fastest growing cancer 6% per year 50% increase in women 15-39 Most common cancer in women 25-29 #1 cancer killer in women 30-35 Affects all age groups No cure for late stage disease
Slide 20: Early Detection is the Only Hope for a Cure
Early Detection is the Only Hope for a Cure ed scars zation ule-out a
Slide 21: How Does MelaFind Work?
How Does MelaFind Work? Hardware: MelaFind acquires multi?spectral data Uses light in 10 wavelengths from 430 nm (blue) to 950 nm (near infrared) Depth up to 2.5 mm into the skin 20 micron?resolution (sees clusters of 3 melanocytes) Software: Sophisticated proprietary automatic algorithms analyze da
Slide 22: Slide 22
Slide 23: Melanoma in situ - All MelaFind High
Melanoma in situ Invasive Melanoma, 0.25 mm Invasive Melanoma, 0.30 mm Invasive Melanoma, 0.40 mm ALL MELAFIND “HIGH” Melanoma in situ Invasive Melanoma, 0.50 mm Melanoma in situ Melanoma in situ Melanoma in situ
Slide 24: —_ vauy Bug meee
—_ vauy Bug meee vii Jvatunncsativeeb ota da apa A Dass cree eummluaoboan DINOTONVOTOROT nT
Slide 25: Low Grade Dysplastic Nevus - All MelaFind Low
Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Seborrheic Keratosis Seborrheic Keratosis ALL MELAFIND “LOW” Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Compound Nevus
Slide 26: Standard images: invasive melanoma vs dysplastic nevus
Example 1 Figure 6. Standard images Invasive melanoma (2P) Low-grade dysplastic nevus (3J) Dermoscopic Clinical close-up Clinical overview Melanoma has eccentric and intense asymmetry at all depths versus benign lesion. Figure 8. Asymmetry images [wavelength (mm) and penetration (mm) and penetractio
Slide 27: Asymmetry images by wavelength and depth
Example 2 (2.5 mm) 430 nm (0.4mm) 460 nm (0.7 mm) 510 nm (0.9 mm) 600 nm (1.7 mm) 660 nm (1.7 mm) 780 nm (2.0 mm) 880 nm (2.2 mn) 950 nm (2.5 mm) © MELA Sciences 2012 Invasive Melanoma Low Grade Dysplastic Nevus Invasive Melanoma Low Grade Dysplastic Nevus Invasive Melanoma Low Grade Dysplastic Nevu
Slide 28: Summary of MelaFind Performance
Summary of MelaFind Performance Pivotal Trial (n = 1612 lesions in primary endpoint) Biopsy 98.3% (112/114*) 95% LCB = 95.1% Sensitivity Average: Biopsy MelaFind: 9.5% p = 0.02 Specificity Dermatologists: 3.7% Adjunctive Reader Study (110 Dermatologists) Biopsy MelaFind: 97% (63/65) p < 0.0001 Sensi
Slide 29: Arch Dermatol. February 20, 2012
Arch Dermotol. February 20, 2012 Dr. Darrell Rigel, New York University 179 attending dermatologists participated 24 pigmented skin lesions (5 melanomas, 19 non-melanomas) Biopsy decision before and after provision of MelaFind result recorded Before After Metric MelaFind MelaFind Comments Sensitivit
Slide 30: Published in Premier Academic Journals
Published in Premier Academic Journals STUDY Online First The Performance of MetaFind A Prospective Multicenter Study Gary Monheit, MD; Armand B. Cognetta, MD; Laura Ferris, MD, Mary Martini, MD; James M. Grichnik, MD, PhD; Martin Mihm, Roy King, MD; Alicia Toledano, ScD; Nikolai Kabelev, BCSc; Obje
Slide 31: German Reader Study
German Reader Study (n = 202 dermatologists) Percent of Number of melanomas Sensitivity Specificity dermatologists Specificity detected by 90% of Sensitivity > 90% dermatologists Arm 1 – 101 dermatologists 70.5% 54% 3 23% 9.2% with clinical information only Arm 2 – 101 dermatologists with clinical 7
Slide 32: Clinically Atypical Pigmented Skin Lesions
Clinically Atypical Pigmented Skin Lesions Pigmented skin lesions having one or more clinical or historical characteristics of melanoma: 14. ABCD: Asymmetry, Border Irregularity, Color Variegation, Diameter > 6 mm1 5. E – Evolving2,3 6. P – Patient’s Concern4,5,6 7. R – Regression7 8. U – Ugly Duckl
Slide 33: Patient In the Clinic
Patient In the Clinic The examining dermatologists’ expertise allows him/her to easily differentiate obviously benign lesions (i.e. freckles)… from an obviously malignant lesion… However, atypical lesions are difficult to differentiate… 33 MelaFind optics by Carl Zeiss MELA Sciences 2012
Slide 34: Summary
Summary Summary Market for melanoma detection is large and growing Significant unmet medical need MelaFind® is a breakthrough product for early detection Largest positive prospective trial ever performed in melanoma detection Launched March 7, 2012 – US & Germany Goal: by March 31, 2013 – 200 system
Slide 35: Evolution of MelaFind
Evolution of MelaFind MelaFind optics by Carl Zeiss MELA Sciences 2012